Business ❯ Pharmaceuticals ❯ Acquisitions

Drug Development

Clinical Trials Bispecific Antibodies Obesity Treatments Brelovitug Inflammatory Diseases ALS Treatment Sleep Disorders Allergy Treatments Skeletal and Muscle Diseases

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

Funded from cash on hand, the purchase brings ALE1 into BioMarin’s rare-skeletal portfolio, signaling a push to scale clinical-stage therapies.

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug